Shares of Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) traded down 3.5% during trading on Wednesday . The stock traded as low as $3.25 and last traded at $3.35. 4,633 shares were traded during mid-day trading, a decline of 73% from the average session volume of 17,048 shares. The stock had previously closed at $3.47.
Analysts Set New Price Targets
Separately, Guggenheim started coverage on shares of Nanobiotix in a research note on Wednesday, August 28th. They set a “buy” rating and a $12.00 price objective for the company.
Read Our Latest Report on NBTX
Nanobiotix Price Performance
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Nanobiotix
- Investing in Construction Stocks
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Start Investing in Real Estate
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Investing In Preferred Stock vs. Common Stock
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
